Ascend-CRC: adapative strategies for clinical evolution and novel dynamics in colorectal cancer
Active Other Transaction Agreement Awarded Last action
- Contract number
- 140D042590032
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $12,074,326
Award facts
- Contract value 52% obligated
-
- $12,074,326.00 Current, with exercised options
- $23,046,918.00 Potential, with all options
- Completion date 24% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institutes of Health Department of Health and Human Services
- NAICS code
- Not on record
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $350,000 | |
| Original award | $11,724,326 |
About this award
The National Institutes of Health awarded an Other Transaction Agreement to The University of Texas M.D. Anderson Cancer Center for ASCEND-CRC (Adaptive Strategies for Clinical Evolution and Novel Dynamics in Colorectal Cancer), a $23,046,918 ceiling-value agreement effective May 20, 2025.
The OTA funds translational oncology research into colorectal cancer prevention, treatment mechanisms, and biomarker discovery. Performance extends through May 19, 2031, with work performed in Houston, Texas.
As an Other Transaction Agreement, this award sits outside the Federal Acquisition Regulation and operates under alternative transaction authority, enabling MD Anderson to structure performance and governance aligned with research-driven milestones rather than traditional federal contracting compliance structures. The ceiling value of $23,046,918 represents the total potential funding available across the performance period.
MD Anderson, a National Cancer Institute-designated Comprehensive Cancer Center and child entity of the University of Texas System, operates as a premier federal research recipient with a portfolio spanning nearly 2,900 awards across 87 agencies. The National Cancer Institute anchors MD Anderson's federal funding, supporting 984 awards representing 79 percent of combined potential value. The center competes full-and-open without SBA set-asides and builds delivery teams internally across its portfolio of clinical trials, preclinical drug development, and specialized medical services.
Quick answers
Who was awarded contract 140D042590032?
140D042590032 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by Interior Business Center (Office of Policy Management and Budget) on May 20, 2025.
How much is contract 140D042590032 worth?
The government has obligated $12,074,326 on 140D042590032. Its potential value, with all options, is $23,046,918.
Which agency awarded contract 140D042590032?
Interior Business Center (Office of Policy Management and Budget) awarded 140D042590032, with funding from National Institutes of Health (Department of Health and Human Services).
Was contract 140D042590032 competed?
The extent of competition for 140D042590032 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award